Advanced search
Publication Cover
Scandinavian Journal of Urology and Nephrology Volume 34, 2000 - Issue 3
Submit an article Journal homepage
14
Views
7
CrossRef citations to date
0
Altmetric
Research Article

Palliative Radiation with a Radiolabeled Diphosphonate (Rhenium-186 Etidronate) in Patients with Hormone-Refractory Disseminated Prostate Carcinoma

Jan Tennvall Department of Oncology, University Hospital, SE-221 85 Lund, Sweden
,
Per-Anders Abrahamsson Department of Oncology, University Hospital, SE-221 85 Lund, Sweden
,
Göran Ahlgren Department of Oncology, University Hospital, SE-221 85 Lund, Sweden
,
Lennart Darte Department of Oncology, University Hospital, SE-221 85 Lund, Sweden
,
Per Flodgren Department of Oncology, University Hospital, SE-221 85 Lund, Sweden
,
Michael Garkavij Department of Oncology, University Hospital, SE-221 85 Lund, Sweden
&
Sven-Erik Strand Department of Oncology, University Hospital, SE-221 85 Lund, Sweden
 show all
Pages 188-193 | Published online: 09 Jul 2009

REFERENCES

  • Ben-Josef E, Porter AT. Radioisotopes in the treatment of bone metastases. Ann Med 1997; 29: 31–5.
  • Lewington VJ. Targeted radionuclide therapy for bone metastases. Eur J Nucl Med 1993; 20: 66–74.
  • Malmberg I, Persson U, Ask A, Tennvall J, Abrahams-son PA. Painful bone metastases in hormone-refractory prostate cancer: economic costs of strontium-89 and/or external radiotherapy. Urology 1997; 50: 747–53.
  • Nilsson S, Westlin J-E. 89-Strontium treatment in prostatic cancer. In: Pharmacological treatment of prostatic cancer. Medical Product Agency; 1993; Vol 3: 123–7.
  • Porter AT, McEwan AJ, Powe JE, Reid R, McGowan DG, Lukka H. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993; 25: 805–13.
  • Quilty PM, Kirk D, Bolger JJ, et al. A comparison of the palliative effects of strontium-89 and external beam therapy in metastatic prostate cancer. Radiother Oncol 1994; 31: 33–40.
  • Serafini AN. Current status of systemic intravenous radiopharmaceuticals for the treatment of painful metastatic bone disease. Int J Radiat Oncol Biol Phys 1994; 30: 1187–94.
  • deKlerk JMH, Van Dijk A, Van het Ship AD, Zonnenberg BA, vanRijk PP. Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases. J Nucl Med 1992; 33: 646–65.
  • Maxon HR, Thomas SR, Herzberg VS, et al. Rhenium-186 hydroxyethylidene diphosphonate for the treatment of painful osseous metastases. Semin Nucl Med 1992; 22: 33–40.
  • Quirijnen JMSP, Shiuw 1111, Zonnenberg BA, et al. Efficacy of rhenium-186-etidronate in prostate cancer patients with metastatic bone pain. J Nucl Med 1996; 37: 1511–5.
  • Schoeneich G, Palmedo H, Dierke-Dzierzon C, Milner SC, Biersack HJ. Rhenium-186 HEDP: palliative radio-nuclide therapy of painful bone metastases. Scand J Urol Nephrol 1997; 31: 445–8.
  • Zonnenberg BA, de Klerk JMH, Quirijnen EVISP. The Utrecht experience with Re-186-etidronate. Basic clini-cal data. Nucl Geneesk Bull 1992; 14: 57–62.
  • Maxon HR, Deutsch EA, Thomas SR, et al. Re-186 (Sn) HEDP for treatment of multiple metastatic foci in bone: human biodistribution and dosimetric studies. Radiology 1988; 166: 501–7.
  • Collins FL, Thompson JK. Reliability and standardiza-tion in the assessment of self-reported headache pain. J Behav Assess 1979; 1: 73–86.
  • Nyren 0, Gustavsson S, Hedin B. Metoder for aft registrera smärta. Läkartidningen 1985; 32–33: 2693–6.
  • SjOden PO, Bates S, Nyren 0. Continuous self-recording of epigastric pain with two rating scales: compliance, authenticity, reliability and sensitivity. J Behav Assess 1983; 5: 327–44.
  • Zubrod CG, Schneiderman MA, Frei E, et al. Appraisal of methods for the study of chemotherapy in man: comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J. Chron Dis 1960; 11: 7–23.
  • Blake GM, Zivnovic MA, McEwan AJ, Ackery DM. Sr-89 therapy: strontium kinetics in disseminated carcino-ma of the prostate. Eur J Nucl Med 1986; 14: 447–54.
  • Cancer Therapy Evaluation Program, Division of Cancer Treatments Common toxicity criteria: guidelines for reporting adverse drug reactions. Bethesda, MD: National Cancer Institute; 1988.
  • Knox SJ. Overview of studies on experimental radio-immunotherapy. Cancer Res 1995; 55: 5832–6.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.